Healthcare Earnings Report — 2026-09-04 to 2026-10-19

25 most recent Healthcare earnings

1. Oct 15, 2026, 8:46 AM ET·RXRX·Healthcare

   Recursion — Q3 2026 Earnings Summary

   RECURSION PHARMACEUTICALS INC

   Sanofi triggered a $10 million milestone payment in Q3 2026, bringing total upfront and milestone receipts to $144 million, with over $300 million in additional milestones still eligible for the optioned program. The optioned candidate is expected to enter Phase 1 clinical trials in 2027, with Sanofi funding and leading all further development and commercialization efforts. Recursion's operational requirements for the optioned candidate have ended, meaning all future payments from this program will result in profit. The collaboration has achieved six progress-based milestones across five programs, with other joint portfolio programs potentially reaching development candidate and progress-based milestones over the next 12 months.

2. Oct 15, 2026, 6:10 AM ET·IDXG·Healthcare

   Interpace Biosciences — Third Quarter 2026 Earnings Summary

   INTERPACE BIOSCIENCES INC

   Preliminary, unaudited Q3 2026 revenue is projected between $10.1 million and $10.4 million, representing 11% to 14% quarter-over-quarter growth from Q2 2026 and 15% to 18% year-over-year growth from Q3 2025. Complete financial results for the quarter remain subject to final closing procedures and independent audit review, with actual results potentially differing materially from the provided range. The company continues to operate as an emerging leader in personalized medicine, focusing on commercialized molecular diagnostic tests for indeterminate thyroid nodules, including ThyGeNEXT® and ThyraMIR®v2. The issuer has filed an SEC registration statement for an offering, and management notes that Q3 revenue figures are not indicative of net income or full-year results.

3. Oct 14, 2026, 8:10 AM ET·MXCT·Healthcare

   MaxCyte — Third Quarter 2026 Earnings Summary

   MAXCYTE INC

   Core business revenue reached $8.1 million in Q3 2026, a 26% year-over-year increase, driven by accelerated instrument purchasing from a large customer. Full year 2026 revenue guidance was raised to approximately $34 million, with specific increases for core business ($28 million), SPL Program ($6 million), and milestone/royalty components. Management anticipates approximately 15% year-over-year growth in core business revenue for the second half of 2026, supported by two pivotal trials under SPL partnerships with potential approval as early as 2027. The company secured its second SPL milestone payment in 2026 and is supporting more late-stage clinical programs than ever before, while royalty revenue from the SPL Program will be finalized in the November 10, 2026, full results.

4. Oct 14, 2026, 6:08 AM ET·VSTM·Healthcare

   Verastem Oncology — October 2026 Earnings Summary

   VERASTEM INC

   Verastem Oncology has appointed Michael P. Bailey as President and CEO effective January 1, 2027, succeeding Daniel Paterson, who will remain on the Board and as an advisor. The company's marketed product, AVMAPKI FAKZYNJA CO-PACK, is advancing through the ongoing Phase 3 confirmatory trial RAMP 301, while its investigational asset VS-7375 has received FDA Fast Track Designation and is enrolling in three registration-directed Phase 2 trials. Management remains confident in the commercialization of AVMAPKI FAKZYNJA CO-PACK and the clinical advancement of VS-7375, though future approval for the marketed product is contingent upon verifying clinical benefit in the confirmatory trial. Key risks include potential negative clinical trial results, failure to close a $50.0 million non-dilutive royalty financing arrangement with Oberland Capital, and regulatory uncertainties regarding FDA workforce reductions.

5. Oct 13, 2026, 4:14 PM ET·VJET·Healthcare

   Flyte Aviation — Third Quarter 2026 Earnings Summary

   FLYTE AVIATION INC

   Preliminary Q3 2026 revenue reached $2.15 million, a 110% sequential increase from Q2 2026, driven by a 150% jump in the aviation segment to $1.87 million and direct-to-consumer revenue exceeding $500,000. Management anticipates continued revenue growth in Q4 2026 and into 2027, supported by fleet expansion and the commencement of Caribbean operations with Canadian permitting nearing completion. The redesigned direct-to-consumer platform launched in May 2026 drove a 185% surge in the user base, adding over 13,000 accounts to reach a total of 20,000 registered users. Financial results are preliminary and unaudited, subject to change pending independent review, while the company faces risks regarding capital needs, regulatory approvals, and converting users to paying customers.

6. Oct 13, 2026, 8:12 AM ET·JNJ·Healthcare

   Johnson & Johnson — Third Quarter 2026 Earnings Summary

   JOHNSON & JOHNSON

   Reported sales reached $25.4 billion (up 5.9% YoY), while reported net earnings and diluted EPS plummeted 95.9% and 95.8% respectively to $210 million and $0.09 due to a one-time special charge for talc litigation, Firefly Bio acquisition, and Sail Biomedicines collaboration; adjusted net earnings and diluted EPS declined 6.8% and 7.5% to $6.339 billion and $2.59. Full-year 2026 guidance was raised, with reported sales midpoint increased to $101.2 billion (7.4% growth) and adjusted EPS midpoint raised to $11.10 (2.9% growth), reflecting a clearer line of sight to double-digit growth by the end of the decade. Strategic portfolio momentum drove segment growth, with Innovative Medicine sales up 7.9% and MedTech up 2.5%, supported by new product approvals including OTTAVA and IMAAVY, alongside the completion of the Firefly Bio acquisition and a strategic collaboration with Sail Biomedicines. Free cash flow strengthened to approximately $15.1 billion (up from $14.226 billion in Q3 2025), while leadership changes included Tom Cavanaugh's appointment as EVP, Worldwide Chairman Innovative Medicine and Jennifer Taubert's retirement.

7. Oct 13, 2026, 6:26 AM ET·ADCT·Healthcare

   ADC Therapeutics — Q3 2026 Earnings Summary

   ADC THERAPEUTICS SA

   Preliminary Q3 2026 net product revenues from ZYNLONTA are estimated at $21.0 million, with cash and cash equivalents totaling $189.2 million as of September 30, 2026. The company secured $86.6 million in gross proceeds from a PIPE transaction and prepaid $70.0 million of its senior secured term loan, reducing the outstanding balance to $50.0 million. Strategic restructuring and capital raises extend the expected cash runway into 2029, with management anticipating net product revenue growth in 2027. Key regulatory milestones include upcoming data presentations for LOTIS-7 and MZL trials in November and December, though risks remain regarding FDA concerns over LOTIS-5 and the requirement to meet a $65.0 million quarterly sales covenant starting December 31, 2026. Amendments to the HCR agreement and Loan Agreement eliminate certain change-of-control payments and amortization schedules, while the company proceeds with efforts to redomicile from Switzerland to Delaware.

8. Oct 13, 2026, 6:19 AM ET·NRIX·Healthcare

   Nurix Therapeutics — Third Quarter 2026 Earnings Summary

   NURIX THERAPEUTICS INC

   Revenue surged to $673.1 million from $7.9 million year-over-year, driven by a $653.2 million license payment from Roche and a $10.0 million milestone from Sanofi, resulting in a net income of $549.8 million versus a net loss of $86.4 million in the prior year. Cash and marketable securities increased to $1.1 billion as of August 31, 2026, providing a runway extending into the second half of 2029, while R&D expenses declined to $79.3 million due to cost-sharing arrangements with Roche. The company advanced bexobrutideg into a Phase 3 registrational trial (DAYBreak CLL-306) comparing the asset to pirtobrutinib, while simultaneously initiating Phase 1b expansion for NX-1607 in four solid tumor indications. Strategic portfolio adjustments included the discontinuation of NX-2127 clinical development and the extension of the Gilead research term, alongside the receipt of a $7 million milestone from Pfizer.

9. Oct 13, 2026, 6:14 AM ET·UNH·Healthcare

   UnitedHealth Group — Third Quarter 2026 Earnings Summary

   UNITEDHEALTH GROUP INC

   Consolidated revenues declined 0.4% year-over-year to $112.7 billion, while earnings from operations surged 53.5% to $6.6 billion, driving diluted EPS to $4.56 from $2.59 and net margin to 3.6% from 2.1%. Full-year 2026 guidance was raised to at least $19.50 per share for earnings and $20.50 for adjusted earnings, supported by a medical cost ratio improvement to 88.4% and an operating cost ratio drop to 12.8%. The company returned $11.2 billion to shareholders year-to-date via $5.0 billion in stock repurchases and $6.2 billion in dividends, while targeting a long-term debt-to-capital ratio of approximately 40.0% by year-end. Strategic initiatives include eliminating 30% of prior approval volume by end-of-year 2026, committing to 100% pass-through of drug rebates by January 2028, and launching a transparent, fee-based pharmacy care model.

10. Oct 13, 2026, 6:01 AM ET·ICCC·Healthcare

    ImmuCell — Q3 2026 Earnings Summary

    IMMUCELL CORP

    Total sales reached $8.0 million in Q3 2026, a 46.0% year-over-year increase, while nine-month sales totaled $25.6 million, up 27.8% compared to the same period in 2025. Growth was broad-based across the portfolio, with Tri-Shield® up 51%, Dual-Force® up 36%, and the new functional feed line up 37% year-over-year, driven by sales team expansion and improved commercial execution. Management announced a strategic shift to discontinue early sales reporting to align with standard SEC practices, committing to full financial metrics only at regular quarterly events. The company operates in the animal health biologics market focusing on calf health solutions, with a conference call scheduled for November 13, 2026, to discuss results.

11. Oct 9, 2026, 5:00 PM ET·COSM·Healthcare

    Cosmos Health — Nine Months Ended September 30, 2026 Earnings Summary

    COSMOS HEALTH INC

    Preliminary nine-month revenue reached $54.3 million, a 19% year-over-year increase, with Q3 revenue rising 2% to $17.4 million; every quarter of 2026 set a record for its respective period. The Company reaffirmed its full-year 2026 revenue outlook to exceed $90 million, projecting Q4 as its strongest quarter historically driven by contract manufacturing orders, seasonal distribution strength, and accelerating US sales. Growth was achieved across all core segments, including record contract manufacturing pipeline volumes of over 32.7 million units and record distribution volumes exceeding 1,500 pharmacies. Strategic expansion includes the acquisition of US-based telehealth firm ZipDoctor, Inc., alongside established R&D partnerships targeting obesity, diabetes, and cancer using AI drug repurposing technologies.

12. Oct 8, 2026, 4:30 PM ET·LUCY·Healthcare

    Innovative Eyewear — Q3 2026 Earnings Summary

    INNOVATIVE EYEWEAR INC

    Preliminary Q3 2026 net sales reached $1.04 million, a 55% year-over-year increase and the highest quarterly revenue in company history, while nine-month sales of $2.8 million (up 66% YoY) already exceed full-year 2025 results. Growth was driven by a 25% rise in direct-to-consumer sales and the initiation of new wholesale programs, including a major U.S. big-box retailer, a Canadian partnership with FYihealth Group, and initial orders from an Australian/New Zealand distributor. Management anticipates new wholesale and international channels will significantly boost Q4 2026 and 2027 growth, coinciding with the holiday launch of the new Lucyd Aero™ collection. Preliminary financial figures are unaudited estimates subject to adjustment, and the company faces ongoing risks regarding financing, going concern status, and Nasdaq listing compliance.

13. Oct 8, 2026, 4:19 PM ET·BKD·Healthcare

    Brookdale Senior Living — September 2026 Earnings Summary

    BROOKDALE SENIOR LIVING INC

    Consolidated weighted average occupancy rose 130 basis points year-over-year to 83.1% in Q3 2026, with sequential growth of 70 basis points from Q2 2026. Month-end occupancy reached 84.6% in September 2026, up from 83.8% in the prior year period, while same-community metrics also showed sequential and year-over-year gains. The company's sequential occupancy growth outperformed NIC stabilized senior housing market results, serving approximately 45,000 residents across 529 communities in 41 states. No specific financial guidance changes, M&A activity, or capital-return announcements were included in the provided summary.

14. Oct 8, 2026, 8:40 AM ET·XAIR·Healthcare

    Beyond Air — Q3 2026 Earnings Summary

    BEYOND AIR INC

    Preliminary Q3 2026 revenue reached $2.3 million, marking a 30% sequential increase and a 27% year-over-year rise, representing the company's highest quarterly revenue to date. Management reaffirmed full-year 2026 revenue guidance of $8 million (excluding second-generation LungFit PH) and 2027 guidance of $16 million to $18 million, contingent on FDA approval of the second-generation system. The second-generation LungFit PH system remains under FDA review via a PMA supplement process, with expectations that its transport capability will position Beyond Air as a single-source nitric oxide provider for U.S. hospital systems. Final Q3 results are subject to financial closing and audit procedures, with full financial reporting scheduled for November 2026.

15. Oct 8, 2026, 7:40 AM ET·HYPR·Healthcare

    Hyperfine — Third Quarter 2026 Earnings Summary

    HYPERFINE INC

    Q3 2026 preliminary revenue is expected to reach approximately $6.0 million, a 53% sequential increase, marking the first quarter where revenue exceeds net cash burn of approximately $5.6 million. Full-year 2026 revenue guidance is reaffirmed at $20 to $22 million, while net cash burn guidance remains unchanged at $26 to $28 million, representing a 10% midpoint decline from 2025. Growth is driven by momentum across health systems, office-based, and mobile verticals, alongside the international rollout of the FDA-cleared Model 2 Swoop AI-powered portable MRI system. The company ended the quarter with approximately $37.9 million in cash and cash equivalents, having raised no financing proceeds during Q3 2026.

16. Oct 8, 2026, 7:17 AM ET·ANGO·Healthcare

    AngioDynamics — Fiscal Year 2027 First Quarter Earnings Summary

    ANGIODYNAMICS INC

    Net sales rose 6.9% year-over-year to $80.9 million, driven by a 13.2% increase in Med Tech sales, while GAAP net loss narrowed to $7.1 million and adjusted EBITDA grew to $5.0 million. The company reiterated full-year fiscal 2027 guidance for net sales ($336.0M–$341.0M), adjusted EBITDA ($13.0M–$16.0M), and gross margin (54%–55%), noting expected margin compression in the second half. CEO Jim Clemmer announced his retirement after ten years, with Eric Honroth appointed as the new President and CEO effective November 2, 2026. Key product lines showed strong growth, including NanoKnife (+29.0% YoY) and AlphaVac (+37.4% YoY), alongside FDA IDE approval for the RELIEF study to expand NanoKnife's use in benign prostatic hyperplasia. The balance sheet remains debt-free with $34.0 million in cash, despite $1.5 million in one-time expenses related to the CEO transition, plant closures, and litigation.

17. Oct 8, 2026, 7:00 AM ET·TLRY·Healthcare

    Tilray Brands — Q1 Fiscal 2027 Earnings Summary

    TILRAY BRANDS INC

    Net revenue rose 23% year-over-year to $257.1 million, driven by an 82% surge in beverage sales to $101.5 million following the BrewDog acquisition, while cannabis revenue declined to $56.1 million; gross margin expanded to 30% from 27%. Reported a net loss of $40.0 million ($0.32/share) versus prior year net income of $1.5 million, with adjusted net loss of $3.0 million ($0.02/share) compared to adjusted net income of $3.4 million; adjusted EBITDA fell to $9.2 million from $10.2 million, impacted by $1.7 million in fuel surcharges. Reaffirmed Fiscal 2027 Adjusted EBITDA guidance of $68 million to $75 million, citing double-digit growth versus Fiscal 2026 and expecting significant strengthening in the fourth quarter due to seasonality. Reduced total outstanding debt by $42 million year-to-date and ended the quarter with a net cash position, while operating expenses increased 83% year-over-year to $101.6 million due to G&A, marketing, and restructuring costs. Strategic milestones include BrewDog achieving Q1 profitability, a partnership with Carlsberg for U.S. market entry scheduled for January 1, 2027, and a reverse stock split effective December 2, 2025.

18. Oct 7, 2026, 4:45 PM ET·PROF·Healthcare

    Profound Medical — Third Quarter 2026 Earnings Summary

    PROFOUND MEDICAL CORP

    Preliminary Q3 2026 total revenue is expected to range between $9.8 million and $10.0 million, representing approximately 85% to 89% year-over-year growth and 292% to 300% sequential growth compared to Q2 2026. Expected revenue exceeds the Bloomberg mean analyst consensus by 45% to 47%, with gross margins anticipated to exceed 70%. Growth is driven by increased commercial activity across the installed base and new customer accounts for flagship platforms TULSA-PRO and Sonalleve, which hold approvals across major global markets. Management characterizes the quarter as a "historic milestone" reflecting strong commercial momentum and a focus on long-term profitability, with full results to be reported after market close on November 5, 2026.

19. Oct 6, 2026, 4:05 PM ET·NEOG·Healthcare

    Neogen — First Quarter Fiscal 2027 Earnings Summary

    NEOGEN CORP

    Total revenue increased 6.5% year-over-year to $222.8 million, with core revenue growth of 8.1%; Adjusted Net Income rose to $17.5 million ($0.08/share) compared to $9.5 million ($0.04/share) in the prior-year quarter. The company raised its full-year fiscal 2027 revenue guidance to $885–$890 million and Adjusted EBITDA guidance to $181–$183 million, citing improved commercial discipline and margin expansion. Strategic initiatives include a collaboration with Hinalea Imaging Corp. for digital food safety solutions, successful validation of a new Petrifilm SKU, and progress toward the expected December 2026 closing of the Genomics business sale to Zoetis Inc. Financial position strengthened with $20.0 million in debt repayments during the quarter, reducing non-current debt to $774.2 million, while operating loss narrowed significantly to $1.8 million from $16.1 million in the prior-year period.

20. Oct 5, 2026, 4:08 PM ET·NEO·Healthcare

    NeoGenomics — Third Quarter 2026 Earnings Summary

    NEOGENOMICS INC

    Preliminary Q3 2026 total revenue is expected at approximately $209 million, driven by a 28% year-over-year increase in next-generation sequencing (NGS) revenue. Full-year total revenue guidance is raised at the midpoint based on Q3 performance, while adjusted EBITDA guidance remains unchanged from July 28, 2026. Effective January 4, 2027, President and COO Warren Stone will succeed Tony Zook as CEO and join the Board, while Zook transitions to Executive Chairman and Chair Lynn Tetrault steps down. Management anticipates durable, profitable growth aligned with long-term strategy, though risks include potential business disruption from leadership transitions and external regulatory or trade policy uncertainties.

21. Oct 5, 2026, 4:07 PM ET·ABBV·Healthcare

    AbbVie Inc. — Q3 2026 Earnings Summary

    ABBVIE INC

    Updated full-year 2026 adjusted diluted EPS guidance lowered to $13.76–$13.96 from $13.87–$14.07, while Q3 adjusted diluted EPS guidance decreased to $3.73–$3.77 from $3.84–$3.88. The guidance reductions reflect a $216 million Q3 acquired IPR&D and milestones expense, with the full-year 2026 expense projected at $1,251 million. Future guidance excludes any impact from acquired IPR&D and milestones expenses beyond Q3 2026 due to forecast reliability limitations.

22. Oct 5, 2026, 9:20 AM ET·NMTC·Healthcare

    NeuroOne — Fiscal Q4 2026 Earnings Summary

    NEUROONE MEDICAL TECHNOLOGIES CORP

    Preliminary fiscal Q4 2026 product revenue is expected at $3.8 million (up 38.4% YoY), while full-year 2026 revenue is projected at $10.5 million (up 15.6% YoY), landing at the top of the previously announced guidance range. The company secured a record $4.5 million product purchase order in September 2026, bringing total open orders for fiscal 2027 shipments to $5.4 million as of September 30, 2026. Future growth is driven by the commercialization of the trigeminal neuralgia system, international expansion, and drug delivery platform advancements, with $3.6 million of the record order expected to ship in Q1 and Q2 of fiscal 2027. Complete audited financial results, including earnings and cash flow, remain preliminary and are scheduled for release in December 2026 alongside the Form 10-K filing.

23. Oct 5, 2026, 8:05 AM ET·SDEV·Healthcare

    Stablecoin Development Corporation — Q3 2026 Earnings Summary

    STABLECOIN DEVELOPMENT CORP

    Generated $4.7 million in staking revenue for the six months ended June 30, 2026, including $2.2 million in Q2, while holding approximately 2.32 billion SKY tokens (approx. 10% of total supply) as of October 2, 2026. Completed a January 2026 Private Placement raising $134.0 million in aggregate gross proceeds ($25.0 million cash and ~$109.0 million in SKY/stablecoins), with $83.2 million remaining available under the $100.0 million ATM offering program as of September 30, 2026. Maintains a strategy to acquire and hold SKY for extended periods to capture protocol-level economics, with no SKY tokens monetized to date and no specific full-year revenue or net income guidance provided. Faces significant concentration risks, including 87.6% of common stock held by two beneficial owners and potential share dilution from pre-funded warrants increasing outstanding shares from ~51.8 million to ~219.3 million. Operates with SKY as the sole approved asset, utilizing self-custody via Fireblocks and Kraken Financial, while noting that historical staking reward rates are not indicative of future performance.

24. Oct 5, 2026, 7:00 AM ET·ALEC·Healthcare

    Alector — Q3 2026 Earnings Summary

    ALECTOR INC

    Secured a $100 million upfront payment from Genentech under a new global license agreement for AL050, with eligibility for up to $1.17 billion in additional milestone payments and tiered royalties. Partnership extends the company's cash runway into 2029 while Genentech assumes full responsibility for the development, regulatory, manufacturing, and commercialization of the AL050 program across all indications. Alector retains ownership of its proprietary ABC platform and rights to its wholly owned pipeline, including plans to advance the AL137 anti-Aβ antibody to multi-cohort clinical data and move Tau and alpha-synuclein siRNA programs through IND-enabling studies. No specific financial guidance changes, M&A activity, or capital-return announcements were disclosed in the summary.

25. Oct 2, 2026, 8:05 AM ET·HYPD·Healthcare

    Hyperion DeFi — Q3 2026 Earnings Summary

    HYPERION DEFI INC

    Retired approximately $8.6 million in legacy debt with no long-term debt outstanding as of September 30, 2026, while holding $14.5 million in cash, cash equivalents, and stablecoins. Executed a share repurchase of 240,124 HYPD common shares at a weighted average price of $3.21, with 15,442,482 shares outstanding as of the period end. Completed strategic transformation away from the legacy Eyenovia biotech brand to focus exclusively on Hyperion DeFi as the first U.S. publicly listed DeFi company building on the Hyperliquid blockchain. Committed to further capital optimization to improve capital structure, leveraging 1.85 million owned Gross HYPE tokens and 47 million autonomously sequestered tokens to generate utility and compounding exposure for shareholders.